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The central amygdala (CeA) plays an important role in opioid addiction. Therefore, we
examined the effects of naloxone-precipitated morphine withdrawal (WD) on GABAergic
transmission in rat CeA neurons using whole-cell recordings with naloxone in the
bath. The basal frequency of miniature inhibitory postsynaptic currents (mIPSCs)
increased in CeA neurons from WD compared to placebo rats. Acute morphine
(10μM) had mixed effects (≥20% change from baseline) on mIPSCs in placebo
and WD rats. In most CeA neurons (64%) from placebo rats, morphine significantly
decreased mIPSC frequency and amplitude. In 32% of placebo neurons, morphine
significantly increased mIPSC amplitudes but had no effect on mIPSC frequency. In
WD rats, acute morphine significantly increased mIPSC frequency but had no effect
on mIPSC amplitude in 41% of CeA neurons. In 45% of cells, acute morphine
significantly decreased mIPSC frequency and amplitude. Pre-treatment with the cyclic
AMP inhibitor (R)-adenosine, cyclic 3′,5′-(hydrogenphosphorothioate) triethylammonium
(RP), prevented acute morphine-induced potentiation of mIPSCs. Pre-treatment of slices
with the Gi/o G-protein subunit inhibitor pertussis toxin (PTX) did not prevent the acute
morphine-induced enhancement or inhibition of mIPSCs. PTX and RP decreased basal
mIPSC frequencies and amplitudes only in WD rats. The results suggest that inhibition
of GABAergic transmission in the CeA by acute morphine is mediated by PTX-insensitive
mechanisms, although PTX-sensitive mechanisms cannot be ruled out for non-morphine
responsive cells; by contrast, potentiation of GABAergic transmission is mediated by
activated cAMP signaling that also mediates the increased basal GABAergic transmission
in WD rats. Our data indicate that during the acute phase of WD, the CeA opioid and
GABAergic systems undergo neuroadaptative changes conditioned by a previous chronic
morphine exposure and dependence.
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INTRODUCTION
The central nucleus of the amygdala (CeA) is a part of the
neuroanatomical entity termed the extended amygdala that also
includes the bed nucleus of the stria terminalis (BNST), and a
transition zone in the medial (shell) subregion of the nucleus
accumbens (Heimer and Alheid, 1991). The extended amygdala
is considered a common anatomical substrate integrating brain
arousal–stress systems with hedonic processing systems produc-
ing the emotional states that promote negative reinforcement
mechanisms associated with the development of addiction (Koob
and Volkow, 2010). In addition, the extended amygdala has long
been hypothesized to play a key role in the emotional component
of pain processing (Neugebauer et al., 2004), and in the medi-
ation of the affective signs of withdrawal from acute morphine
treatment (Criner et al., 2007) and the motivational aspects of
chronic opiate withdrawal (Frenois et al., 2002). The CeA has a
key function in the acute reinforcing actions of drugs of abuse,
including opioids (Koob and Volkow, 2010), and is considered to
be critical for the affective component of acute and chronic opiate
withdrawal (Jin et al., 2004).
Our recent study and those from others have shown that not
all CeA neurons are responsive to acute opioids, suggesting the
presence of neuronal subpopulations mediating the opioid effects
in the CeA (Zhu and Pan, 2004, 2005; Finnegan et al., 2005,
2006; Chieng et al., 2006; Bajo et al., 2011). Most CeA neu-
rons in rodents are GABAergic neurons with inhibitory recurrent
or feed-forward connections, as well as inhibitory projections
to brainstem (Sun and Cassell, 1993; Cassell et al., 1999) and
other extended amygdala areas such as BNST (Weller and Smith,
1982; Veinante and Freund-Mercier, 1998). Activation of opioid
receptors is reported to induce inhibitory potassium currents in
subpopulations of CeA neurons characterized by expression of
mu (MORs) and kappa (KORs) opioid receptors (Zhu and Pan,
2004; Chieng et al., 2006).
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MORs tonically inhibit GABAergic transmission in the CeA
and acute activation of MORs diminishes GABAergic transmis-
sion in most CeA neurons, predominantly by reducing presy-
naptic GABA release (Kang-Park et al., 2009; Bajo et al., 2011).
Moreover, in the CeA neurons projecting to periaqueductal gray
area (PAG), presynaptic MORs primarily attenuate GABAergic
synaptic transmission (Finnegan et al., 2005). In the central
extended amygdala chronic morphine induces transcriptional
plasticity characterized by a dysregulation of expression of genes
involved in neurogenesis, cell growth and signaling (Bajo et al.,
2006; Befort et al., 2008). Heroin self-administration alters
gene expression of opioids in the CeA (Solecki et al., 2009).
In amygdala, chronic heroin administration decreases opioid
agonist-stimulated GTP binding but does not alter MOR bind-
ing autoradiography (Sim-Selley et al., 2000; Maher et al., 2005).
In contrast, no changes in the GTP binding have been observed
in amygdala after chronic morphine (Sim et al., 1996) or in the
CeA during morphine withdrawal (Kirschke et al., 2002). The
ERK signaling pathway in the CeA is critical in induction of mor-
phine craving (Li et al., 2008). We previously found no significant
effect on basal GABAergic transmission during chronic morphine
treatment, suggesting a lack of effect of long-term morphine,
or tolerance and alterations of MOR-dependent postsynaptic
mechanisms (Bajo et al., 2011).
Repeated morphine-conditioning treatment enhances gluta-
mate synaptic strength and recruits new functional DORs on
glutamate synapses in the CeA (Sim et al., 1996; Sim-Selley et al.,
2000; Kirschke et al., 2002; Maher et al., 2005; Befort et al.,
2008; Li et al., 2008; Bie et al., 2009; Solecki et al., 2009). These
findings indicate that chronic opioid exposure followed by subse-
quent withdrawal induces complex neuroadaptation of the opioid
and other systems in the CeA. The mechanisms mediating such
adaptive changes likely involve both pre- and postsynaptic mech-
anisms and lead to alteration of MOR-dependent modulation
of the physiological and synaptic properties of the amygdala
neurons.
In a previous study (Bajo et al., 2011) characterizing adap-
tation of the GABAergic system during continuous chronic
morphine exposure we found a tolerance to inhibitory effects
of acute activation of MORs on presynaptic GABA release in
the CeA. Moreover, we found very similar effects of acute
application of MOR agonist and antagonist on GABAergic trans-
mission in placebo- and morphine-treated rats, further suggest-
ing a homeostatic neuroadaptation of the CeA opioid system
and MOR-dependent regulation of CeA GABAergic transmis-
sion. Interestingly, we observed significant effects of acute MOR
agonist on the mIPSC amplitudes only in CeA of morphine-
treated rats, but not of placebo rats, suggesting postsynaptic
adaptative changes of the MOR system during chronic mor-
phine treatment (Bajo et al., 2011). Therefore, in the present
study, we aimed to assess the changes of the MOR-dependent
modulation of GABAergic transmission associated with an early
phase of morphine withdrawal. We hypothesized that, as in
other brain regions (Christie, 2008), the CeA opioid system
will be over-activated during morphine withdrawal. Therefore,
here we have examined basal CeA GABAergic transmission
during morphine withdrawal and challenged the MOR system
by acute morphine application to examine the influence of
activated MORs on GABAergic transmission at a withdrawal
time-point. To model naloxone-precipitated morphine with-
drawal, we performed all recordings with naloxone (placebo
rats) and naloxone plus morphine co-application (morphine
WD rats) in the bath solution. In the ventral tegmental area
Madhavan et al. (2010a) found an acute morphine-induced
facilitation of GABAergic transmission, indicating a switch in
the coupling of MORs from inhibitory Gi/o subunit to stim-
ulatory Gs subunit signaling. These findings are in accord
with our preliminary report on the facilitatory effects of acute
morphine application on CeA GABAergic transmission during
spontaneous morphine withdrawal (Bajo et al., 2008, 2009).
Thus, we hypothesized that adaptative changes of MOR and
GABAergic systems similar to those reported by Madhavan
et al. are present in CeA during naloxone-precipitated morphine
withdrawal.
Our results show alterations of the basal GABAergic trans-
mission in morphine WD rats, and acute morphine-induced
increases and decreases of CeA GABAergic transmission in
both placebo and WD rats. Furthermore, as Gi/o are the pri-
mary G subunits coupled to MORs (Laugwitz et al., 1993;
Clark et al., 2006), we hypothesized that inhibitory effects of
acute morphine application on CeA GABAergic transmission
are mediated by Gi/o, whereas the facilitatory effects of acute
morphine involve Gs subunits and activation of cAMP-PKA
signaling. To test this hypothesis, we applied pertussis toxin
(PTX), an inhibitor of Gi/o subunits, and (R)-adenosine, cyclic
3′,5′-(hydrogenphosphorothioate) triethylammonium (RP), an
inhibitor of the cAMP-PKA pathway. We found that PTX-
insensitive mechanisms are involved in the acute morphine-
induced inhibition of GABAergic transmission, but we cannot
completely rule out an involvement of PTX-sensitive mecha-
nisms in the inhibitory effects of acute morphine. However,
activated cAMP signaling appears to mediate the morphine
withdrawal-elicited increase of basal GABAergic transmission and




Male Sprague-Dawley rats (weights at the time of electrophysio-
logical recordings: placebo: 218 ± 8 g; n = 25; morphine: 216 ±
11 g; n = 24) were housed in a temperature- and humidity-
controlled room on a 12-h light/dark cycle (lights on at 6:00
am) with food and water available ad libitum. We used the stan-
dard morphine pellet method, with two morphine (75mg of
morphine/pellet) or placebo pellets implanted subcutaneously
(Gold et al., 1994; Bajo et al., 2011). To precipitate morphine
withdrawal, we injected naloxone (1mg/kg) subcutaneously. Just
prior to sacrifice, the rats were then observed for development
of physical signs of morphine withdrawal, represented by diar-
rhea and wet dog shakes. These signs developed solely in chronic
morphine-treated rats within 15–20min after the naloxone injec-
tion.We conducted all care and surgical procedures in accordance
with the National Institutes of Health Guide for the Care and Use
of Laboratory Animals and with the Institutional Animal Care
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and Use Committee (IACUC) policies of The Scripps Research
Institute.
SLICE PREPARATION
Rats were anesthetized with 3% isoflurane, decapitated and the
brains quickly removed and placed in ice-cold oxygenated arti-
ficial cerebrospinal fluid (ACSF; in mM: 130 NaCl, 3.5 KCl, 1.25
NaH2PO4.H2O, 1.5MgSO4.7H2O, 2.0 CaCl2.2H2O, 24 NaHCO3,
and 10 glucose) gassed with 95% O2 and 5% CO2. We cut
coronal slices (300–400μM) containing the CeA using a Leica
1000S vibrotome cutter (Campden, Lafayette, Indiana). To sim-
ulate in vivo conditions of naloxone-induced withdrawal during
our recordings in morphine dependent rats, we included nalox-
one (10μM) andmorphine (1μM) in the cutting solution during
slice preparation and in the bath during recordings. The slice
preparation and recordings from placebo (morphine naïve) rats
were conducted in the ACSF containing naloxone (10μM). We
performed recordings within 1–6 h after slice cutting. Drugs were
added to the ACSF from stock solutions (flow rate 2–4ml/min)
in known concentrations and we took all physiological measures
before acute morphine (baseline) and during its superfusion (5–
15min). To avoid multiple morphine applications, we recorded
from a single neuron from each slice and discarded all other slices
exposed to acute morphine.
WHOLE-CELL PATCH-CLAMP RECORDING
We performed whole-cell patch-clamp recording in voltage clamp
mode as described previously (Bajo et al., 2011). To facilitate
cell identification, we used infrared/DIC visualization, followed
by digitization and image enhancement, via an upright, fixed-
stage Olympus microscope. We used a 40X water immersion lens
and image processing with EXI Blue CCD camera (QImaging
software, Surrey, BC, Canada). We isolated miniature GABAA
IPSCs (mIPSCs) pharmacologically by applying 20μM DNQX,
30μM DL-AP5, and 1μM CGP 52432 and 1μM tetrodotoxin
(TTX) to the bath. To evaluate a role for Gi/o and cAMP, we
pre-treated CeA slices with 250 ng/ml of PTX for 0.5 up to 6 h,
an inhibitor of Gi/o subunits, and 500 nM (R)-adenosine, cyclic
3′,5′-(hydrogenphosphorothioate) triethylammonium (RP), an
inhibitor of cAMP signaling, for 15min prior to and through-
out the recordings. All mIPSC recordings were held at—60mV
membrane potential and were made with 3–4 M pipettes
filled with an internal solution containing (in mM): 135 KCl,
10 HEPES, 2 MgCl2, 0.5 EGTA, 5 ATP, and 1 GTP (the latter
two added fresh on the day of recording), pH 7.3–7.4, osmolar-
ity 275–290mOsm. For data acqusition, we used a Multiclamp
700B (Molecular Devices) and pClamp 10.2 software (Molecular
Devices).
DATA ANALYSIS AND STATISTICS
To analyze data acquired from whole-cell recordings, we used
Clampfit 10.2 (Molecular Devices) and MiniAnalysis 5.1 software
(Synaptosoft, Leonia, NJ), respectively. We used GraphPad
Prism 5.0 software (GraphPad Software, San Diego, CA) for
all statistical analyses of results obtained by intracellular and
whole-cell recordings. Because not all CeA neurons are respon-
sive to MOR agonists (Zhu and Pan, 2004; Chieng et al., 2006),
we used a change of 20% of control values as a threshold for
dividing the cells into MOR agonist-sensitive and -insensitive
groups (Bajo et al., 2011). We accepted statistical significance
at the p < 0.05 level using One- and Two-Way ANOVA, the
Kolmogorov-Smirnoff test, and t-tests.
DRUGS
We purchased CGP 55845A, DNQX, DL-AP5, and PTX from
Tocris Biosciences (Ellisville, MI), TTX from Calbiochem (San
Diego, CA) and RP from Sigma-Aldrich (St. Luis, MO).
Morphine sulphate, morphine, and placebo pellets were provided
by the National Institute on Drug Abuse.
RESULTS
EFFECTS OF MORPHINE AND OPIATE WITHDRAWAL
We recorded miniature IPSCs from 76 CeA neurons using whole-
cell recordings in voltage-clamp mode. The basal frequencies
of the CeA mIPSCs were significantly [t(52) = 3.1, p < 0.01]
increased in the morphine withdrawn (WD) rats (0.9 ± 0.1Hz,
n = 29) compared to the placebo rats (0.5 ± 0.1Hz, n = 25),
suggesting an increase in presynaptic GABA release during
naloxone-precipitated WD. There was no significant difference
in the mean mIPSC amplitudes between the CeAs of placebo
(57.9 ± 3.6 pA, n = 25) and morphine WD rats [65.6 ± 3.5 pA,
n = 29; t(52) = 1.8, p > 0.05; Figure 1].
Acute application of morphine (10μM) produced mixed
effects on the mIPSC frequencies and amplitudes in both placebo
and morphine WD rats. We used a 20% change in the fre-
quencies and/or amplitudes of the mIPSCs as the selection cri-
terion (Bajo et al., 2011) and divided the CeA neurons into
three groups: no response, increase, or decrease in the mIPSC
measures. In placebo rats, the majority of CeA neurons (16 of
25 neurons) responded to acute superfused morphine with a
decrease in both frequency [73.0 ± 4.3% of baseline; t(15) = 2.4,
p < 0.05] and amplitude [81.4 ± 2.9% of baseline; t(15) = 5.4,
p < 0.05] of the mIPSCs (Figures 2A–C,G,H). Another subpop-
ulation (8 of 25 neurons) of placebo CeA neurons responded
to acute morphine application with a significant increase in the
amplitude [122.3 ± 7.8% of baseline, n = 8; t(7) = 3.7, p < 0.05]
but not frequency of mIPSCs [129.2 ± 9.0% of baseline, t(7) =
1.8, p > 0.05; Figures 2D–H]. In the morphine WD rats, acute
morphine application decreased both frequency [71.0 ± 4.2%
of baseline, n = 13; t(12) = 4.2, p < 0.05] as well as amplitude
[86.2 ± 3.8%, t(12) = 3.3, p < 0.05] of the mIPSCs in 13 of 29
CeA neurons. Another subpopulation of the CeA neurons (12
of 29 cells) responded to acute morphine with a significant
increase in the frequency [163.9 ± 18.6%, n = 12; t(11) = 3.3,
p < 0.01] but not the amplitude of mIPSCs [116.8 ± 13.3%,
t(11) = 1.3, p > 0.05; Figures 2D–H]. Two-Way ANOVA, com-
paring the enhancing effects of acute morphine on the mIPSC
frequencies between CeA neurons from placebo and morphine
pellet treated and WD rats, showed significant main effects of
acute morphine application [F(1, 18) = 10.8, p < 0.01] and pellet
treatment [F(1, 18) = 7.9, p < 0.01], and no significant interac-
tion between acute morphine and pellet treatment [F(1, 18) =
3.5, p = 0.08]. The ANOVA analysis also showed a significant
main effect of acute morphine [F(1, 18) = 5.9, p < 0.05] but no
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FIGURE 1 | Naloxone-precipitated withdrawal increases GABA release
in the CeA from morphine-dependent rats. (A) Representative GABAA
mIPSC recordings (in the presence of TTX) from CeA neurons from placebo
(left column) and morphine-withdrawn rats (right column), respectively. (B)
The mean basal mIPSC frequencies in CeA neurons (n = 29) from
morphine-withdrawn rats were significantly increased (p < 0.01) compared
to neurons (n = 25) from placebo (morphine naïve) rats. (C) There was no
significant difference in the mean basal mIPSC amplitude between CeA
neurons from placebo and morphine withdrawn rats. The statistical
significance ∗∗p < 0.01.
main effect of the pellet treatment [F(1, 18) = 0.5, p > 0.05] nor
acute morphine × pellet treatment interaction [F(1, 18) = 0.1,
p > 0.05] on the mIPSC amplitudes. The comparison of the
inhibitory effects of acute morphine on the mIPSCs between
placebo and morphine WD rats showed a significant main
effect of acute morphine [F(1, 26) = 21.9, p < 0.01] and pel-
let treatment [F(1, 26) = 6.3, p < 0.05] on mIPSC frequencies
but no interaction between acute morphine and pellet treat-
ment [F(1, 26) = 2.4, p > 0.05]. Similarly, we found a significant
main effect of acute morphine [F(1, 26) = 34.5, p < 0.01] and
pellet treatment [F(1, 26) = 5.1, p < 0.05] on mIPSC amplitudes
associated with no interaction between acute morphine and pel-
let treatment [F(1, 26) = 0.7, p > 0.05]. Acute morphine had no
effect on either the frequency or amplitude in the remaining 1 cell
from placebo or 5 cells frommorphineWD rats (data not shown).
These results suggest that regardless of their previous morphine
exposure, some CeA neurons adapt to prolonged (<8 h) expo-
sure to naloxone during an induction of naloxone-precipitated
withdrawal, by reversing the inhibitory effects of the acute mor-
phine on GABAergic transmission. The results are summarized in
Table 1.
SIGNALING PATHWAYS INVOLVED IN MORPHINE ANDWITHDRAWAL
EFFECTS
We hypothesized that the observed mixed effects of acute mor-
phine on GABAergic transmission in the CeA are caused by a
difference in coupling of MORs to G protein subunits, result-
ing in activation instead of inhibition of the cyclic AMP (cAMP)
pathway. To test this possible mechanism, we pre-incubated CeA
slices with 250 ng/ml PTX, an inhibitor of Gi/o,or 500 nM RP,
the cAMP signaling inhibitor. In CeA of placebo rats, the PTX
(n = 9 cells from 4 rats) or RP (n = 16 cells from 4 rats) pre-
treatments had no significant effects on basal mIPSC frequencies
[F(2,49) = 0.2, p > 0.05] or amplitudes [F(2,49) = 1.3, p > 0.05],
compared to the untreated CeA neurons (Figure 3). These data
suggest that PTX-sensitive Gi/o signaling and cAMP-PKA signal-
ing are not critically involved in the basal GABAergic transmis-
sion in the CeA of the placebo rats during prolonged naloxone
exposure.
In the morphine WD rats, there were significant differences
in the basal mean frequency [F(2, 47) = 10, p < 0.01] and ampli-
tude [F(2,36) = 12.3, p < 0.01] between PTX-, RP-pretreated
and untreated CeA neurons. We found a significant reduction
(Bonferoni test, p < 0.05) of the mIPSC frequencies in CeA neu-
rons pretreated with PTX (0.3 ± 0.07 pA, n = 6 cells from 4
rats) or RP (0.4 ± 0.05 pA, n = 13 cells from 6 rats) compared
to the untreated CeA cells (Figure 3). The Bonferroni’s post-hoc
test showed a significant decrease in the mean mIPSC ampli-
tudes following RP (46.4 ± 4.2 pA) but not PTX pretreatment
(51.3 ± 5.1 pA) compared to untreated CeA neurons (66.9 ±
3.4 pA, n = 29; p < 0.05). These findings suggest that both
Gi/oand activated cAMP-PKA signaling pathways are involved in
the modulation of increased presynaptic GABA release, whereas
activated cAMP-PKA signaling may be involved also in the post-
synaptic regulation of GABAergic transmission in the CeA during
naloxone-precipitated withdrawal.
After pre-incubation of CeA slices with RP for 15–30min,
acute morphine significantly decreased themeanmIPSC frequen-
cies [F(1, 37) = 16.23, p < 0.05] and amplitudes [F(1, 37) = 5.8,
p < 0.05; t(10) = 12.5, p < 0.05] in 10 of 15 CeA neurons from
4 placebo rats (frequency: 62.2 ± 5.7% of baseline; amplitude:
87.1 ± 4.6%of baseline) and 9 of 15 neurons from 6WD rats (fre-
quency: 63.8 ± 3.8% of baseline; amplitude: 95.1 ± 5.7% of base-
line; Figures 4A–C). There was no significant main effect of pellet
treatment or interaction between acutemorphine and pellet treat-
ment. In placebo rats, there were no significant effects of acute
morphine on the mIPSCs in 4 cells, and no potentiation of the
mIPSC frequency and amplitude in one neuron. In the rest of the
CeA neurons (4 of 13 cells) from WD rats, acute morphine had
no significant effects on mIPSC frequency or amplitude. Thus,
RP pre-incubation prevented the CeA neurons from responding
to acute morphine with increases in mIPSCs in placebo (Chi-
square test, p < 0.05) or WD (Chi-square test, p < 0.05) rats
(Figure 4D). These results suggest that activation of the cAMP
signaling pathway plays a key role in the acute morphine-induced
increase in the CeA GABAergic transmission in a subpopulation
of CeA neurons, and also may be involved in the acute morphine
effects mediated via postsynaptic mechanisms in both placebo
and morphine WD rats.
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FIGURE 2 | Acute morphine has mixed effects on GABAergic
transmission in the CeA following naloxone-precipitated withdrawal.
(A) Representative recordings from the CeA neurons responding to acute
morphine (10μM) application by an inhibition of mISPCs from placebo (top
panel) and morphine withdrawn (bottom panel) rats. (B,C) In 64% of neurons
from placebo and 45% from morphine-withdrawn rats, acute morphine
decreased the frequency and amplitude of the mIPSCs. (D) Representative
recordings of CeA neurons from placebo and morphine-withdrawn rats that
responded to acute morphine by an increase in the mIPSCs. (E,F) Whereas
32% of CeA neurons from placebo rats responded to acute morphine by an
increase in mIPSC amplitudes, 41% of neurons from morphine-withdrawn
rats responded to acute morphine by an increase in the mIPSC frequencies.
(G,H) 2-D scatter graphs showing distribution of baseline (x-axis) and acute
morphine (y-axis) mIPSC frequencies (G) and amplitudes (H) of individual
acute morphine-responsive CeA neurons. The statistical significance ∗ and ∗∗
were set at p < 0.05 and at p < 0.01, respectively.
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Table 1 | Summary of acute morphine-induced changes in mIPSCs in
CeA neurons of placebo and morphine (WD) pellet–treated rats.
Pellet Basal mIPSCs Acute Morphine (10 µM)
treatment Frequency Amplitude Frequency Amplitude
(Hz) (pA) (Hz) (pA)
Placebo 0.52±0.09 57.9±3.6 ↓ ↑ and ↓
WD 0.91±0.09* 66.4±3.4 ↑ and ↓ ↓
*Significant difference between placebo and WD rats; ↓, significant decrease;
↑, significant increase.
As PTX is an inhibitor of Gi/o, we expected to prevent the
acute morphine-induced decrease in the amplitudes and/or fre-
quencies of CeA mIPSCs. Surprisingly, PTX pre-incubation did
not completely prevent acute morphine-induced inhibition or
enhancement of CeA mIPSCs from placebo or morphine WD
rats. In placebo rats, acute morphine decreased mean mIPSC fre-
quencies or amplitude in 4 of 9 neurons, as determined by the
Kolmogorov-Smirnoff test for individual cells (data not shown).
Similarly, acute morphine application increased the amplitude or
frequency of mIPSCs in an additional 4 cells. In WD rats, PTX
also did not prevent the acute morphine reduction or enhance-
ment of the mIPSCs: 2 of 6 neurons still showed increased mean
frequencies (178.0 ± 29.4% of baseline, n = 2 from 2 rats) or 3
neurons showed decreases in both frequency (71.0% of baseline,
n = 3 from 3 rats) and amplitude (82.2% of baseline) of the mIP-
SCs, respectively (data not shown). These findings suggest that in
addition to a PTX-sensitive Gi/o pathway, other PTX-insensitive
mechanisms may be involved in the inhibitory effects of acute
morphine on GABAergic transmission in the CeA.
DISCUSSION
In this study, we assessed neuronal adaptations of the GABAergic
and opioid systems in the CeA during naloxone-precipitatedmor-
phine withdrawal. We found increased CeA basal GABA release
in morphine dependent rats during naloxone-precipitated with-
drawal. Acute morphine application had mixed effects on the
GABAergic transmission in the CeA neurons in this model of
naloxone-induced morphine withdrawal. Our study also showed
that a continuous exposure to naloxone during the naloxone-
precipitatedWD does not prevent acute morphine-inducedmod-
ulation of GABAergic transmission. Under our experimental
conditions, the acute morphine-induced inhibition of GABAergic
transmission is very likely mediated by PTX-insensitive mecha-
nisms in many CeA neurons, but we cannot rule out the possi-
bility that a PTX-sensitive mechanism is involved in some CeA
neurons as well. On the other hand, an activated cAMP signaling
pathway is a likely molecular mechanism underlying the increase
in basal GABAergic transmission and acute morphine-induced
potentiation of GABAergic transmission in the CeA.
To model the naloxone-precipitated morphine withdrawal, we
performed all recordings with naloxone and naloxone plus mor-
phine co-application in the bath during recordings from the CeA
neurons from the placebo and morphine WD rats, respectively.
It has been shown that there is a tonic inhibition of GABAergic
transmission mediated by MORs in the CeA. In addition, acute
FIGURE 3 | Effects of Gi/o and cAMP inhibitors on CeA basal
GABAergic transmission. (A) The Gi/o inhibitor PTX (250 ng/ml) and cAMP
inhibitor RP (500 nM) prevented an increase in mIPSC frequencies in CeA
neurons (PTX: n = 6 and RP: n = 13) from morphine WD rats. In contrast,
these agents had no effects on mIPSC frequencies in neurons (PTX: n = 9
and RP: n = 16) from placebo rats. The values presented as untreated CeA
neurons correspond to those neurons shown in Figure 1A. (B) By
comparison to the untreated CeA neurons (the same data presented in
Figure 1B), RP significantly reduced mean basal mIPSC amplitudes only in
neurons from morphine WD rats. In the presence of PTX, basal mIPSC
amplitudes were not significantly different between placebo and morphine
WD rats. Statistical significance: ∗p < 0.05, was calculated by One-Way
ANOVA.
application of MOR antagonists prevents the effects of acute
MOR agonists on GABAergic transmission (Zhu and Pan, 2004;
Finnegan et al., 2005; Kang-Park et al., 2009; Bajo et al., 2011).
Thus, our findings that acute morphine modulates GABAergic
transmission in the CeA despite the presence of naloxone in the
bath may suggest an incomplete inhibition of the CeA opioid
system by naloxone or development of tolerance to naloxone
during the naloxone-precipitated withdrawal. Similarly, previous
studies have shown attenuation of naloxone-precipitated with-
drawal symptoms by inhibition of enkephalinase activity (sug-
gesting an increase in endogenous enkephalin levels; (Haffmans
and Dzoljic, 1987; Haffmans et al., 1987) and induced heroin
reinstatement during naloxone-precipitated WD by a priming
injection of heroin (Shaham et al., 1996). Mechanisms underlying
these paradoxical findings may involve both opioid-dependent
and non-opioid-dependent (e.g., activation of glia via toll-like
receptor 4) (Hutchinson et al., 2007, 2012; Watkins et al., 2009;
Lewis et al., 2012) mechanisms. With regard to opioid dependent
mechanisms, we hypothesize that a prolonged naloxone exposure
Frontiers in Integrative Neuroscience www.frontiersin.org June 2014 | Volume 8 | Article 45 | 6
Bajo et al. CeA GABA during morphine withdrawal
FIGURE 4 | RP inhibition of cAMP prevents enhancement of GABAergic
transmission induced by acute morphine application. (A) Represen-
tative recordings from CeA neurons from placebo and morphine WD rats
pre-treated with RP. (B) After RP (500 nM) pre-treatment, acute morphine
(10μM) gave a significant main inhibitory effect on mean mIPSC
frequencies and amplitudes (C) of CeA neurons from placebo (n = 10) and
morphine-withdrawn (n = 9) rats. Statistical significance (#p < 0.05 and
##p < 0.01) was calculated by Two-Way ANOVA. (D) In CeA from both
placebo and WD rats, RP-pretreatment significantly reduced the number of
CeA neurons responding to acute morphine by an increase in mIPSCs, as
calculated by Chi-square test (∗p < 0.05).
(more than 1 h) could lead to a continuous blockade of the
MOR-dependent tonic inhibition of GABAergic transmission and
elicit tolerance and/or adaptation of the CeA opioid system.
Changes in messaging pathways, especially in cAMP and PKA
signaling, and perhaps Gz activation as well, may develop under
the continuous presence of naloxone and thus mediate the acute
morphine modulation of the GABAergic transmission.
The effects of naloxone on the opioid system are deter-
mined by a previous opioid treatment. Naloxone acts as a
neutral agonist in MOR/DOR agonist-naïve cells cultures and
as an inverse agonist after a previous MOR/DOR exposure
(Wang et al., 2001). Thus, our findings of increased basal GABA
release in some CeA neurons from the morphine WD rats
compared to placebo rats may support the idea of naloxone
acting as an inverse agonist in the morphine WD rats or as a
neutral antagonist in the CeA in placebo rats. The increased
GABA release in the CeA during naloxone-precipitated with-
drawal is in accord with the enhanced GABAergic synaptic
transmission found in other brain regions after such naloxone
induced WD (Bonci and Williams, 1997; Chieng and Williams,
1998; Ingram et al., 1998; Jolas et al., 2000; Hack et al., 2003;
Madhavan et al., 2010a,b). Our group (Bajo et al., 2008, 2009)
and others (Madhavan et al., 2010a; Meye et al., 2012) reported
that acute morphine increases GABAergic transmission dur-
ing spontaneously-morphine WD rats and naloxone-precipitated
withdrawal combined with recordings without naloxone showed
similar inverse effects of acute MOR agonists on GABAergic
transmission during morphine withdrawal. Overall, these find-
ings indicate that MOR-induced potentiation of GABAergic
transmission during morphine withdrawal is a general neu-
roadaptive mechanism associated with morphine withdrawal.
However, a role for non-opioid mechanisms cannot be ruled out
and require further investigation.
The molecular mechanism of both the action-potential inde-
pendent increase in GABA release and the morphine-induced
potentiation of GABAergic transmission in the CeA appears to
be mediated by a hyperactivation of cAMP, because RP pre-
treatment decreased the mean frequencies of basal mIPSCs and
prevented the acute morphine enhancement of GABAergic trans-
mission. There are numerous studies reporting a compensatory
increase in PGE1- or forskolin-stimulated adenylyl cyclase activ-
ity in neuronal cells chronically exposed to opioids upon removal
of the opioids (Bailey and Connor, 2005; Williams et al., 2013).
A superactivation of cAMP also has been reported to mediate
DAMGO-induced enhancement of GABA transmission in the
VTA (Madhavan et al., 2010a; Meye et al., 2012). In general, the
excitatory effects occurring during opioid tolerance and depen-
dence is thought to be mediated by an additive or synergistic
effect of a loss of adenylyl cyclase inhibition by Gi/o and stim-
ulation of adenylyl cyclases by both Gs and its associated Gβγ
(Wang and Burns, 2006). Thus, we assume that bothmechanisms,
a switch in MOR G protein coupling from cAMP-inhibitory Gi/o
to cAMP-stimulatory Gs (Crain and Shen, 1998; Wang et al.,
2005) and a stimulation of adenylyl cyclase by Gβγ subunits,
may mediate superactivation of cAMP during morphine with-
drawal in the CeA. It has been shown that chronic morphine
treatment maintains the association of Gs withMORs and dimin-
ishes the association of Gi/o with MORs (Chakrabarti et al., 2005;
Wang and Burns, 2006). Studies on cell cultures also showed
that chronic morphine-induced interaction of Gβγ with adeny-
lyl cyclase can occur without alteration of the G protein coupling
profile (Chakrabarti et al., 2001). These findings support the
hypothesis that both of these events can contribute to enhanced
activation of the cAMP following chronic morphine treatment
(Wang et al., 2005; Wang and Burns, 2006). The chronic mor-
phine treatment-induced reduction of MOR-Gi/o coupling, par-
alleled with increased Gs coupling and a direct interaction of
Gβγ with adenylate cyclase, has been found in the striatum,
periaqueductal gray, and spinal cord (Kitanaka et al., 2008).
MORs preferentially couple to the PTX-sensitive G pro-
teins, Gi, and Go, to inhibit the adenylyl cyclase/cAMP pathway
(Connor and Christie, 1999). We found that Gi/o plays a role
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in the action potential-independent GABA release in CeA, as
PTX pre-treatment reduced the mean frequencies of mIPSCs in
the CeA neurons from morphine WD rats but had no effects
in placebo rats. This concurs with studies in cultured cell lines
showing opioid-induced adenylyl cyclase superactivation that was
sensitive to PTX treatment, implicating the involvement of PTX-
sensitive Gi/o proteins in mediating these adaptive responses (Tso
and Wong, 2000; Steiner et al., 2005). Another possibility may
include a PTX-pretreatment induced substitution of Gi/o by Gz.
Despite a similarity in inhibition of adenylyl cyclase and K+ chan-
nels, Gz exhibits unique biochemical,and regulatory properties
(Ho and Wong, 2001) that may underlie the decrease in basal
mIPSCs observed in the CeA of WD rats. Our results showing
acute morphine-induced reduction of GABAergic transmission
following PTX-pre-treatment of the CeA slices suggest that both
PTX-sensitive as well as PTX-insensitive mechanisms, such as Gz
or Gβγ subunits, may be involved in the inhibitory effects of acute
morphine on GABAergic transmission in the CeA. MORs have
been reported to modulate both PTX-sensitive Gi/oproteins as
well as the PTX-insensitive Gz proteins (Sanchez-Blazquez et al.,
2000). Gz also inhibits adenylyl cyclase (Sadana and Dessauer,
2009) and is thought to be involved in the regulation of ion chan-
nel activities and exocytosis (Ho and Wong, 2001). Morphine is a
strong activator of Gz (Garzon et al., 1998), and the antinocicep-
tive activity of morphine (Sanchez-Blazquez et al., 2001; Garzon
et al., 2011) and analgesic desensitization are strongly decreased
after Gz depletion (Garzon et al., 2009). As Gz is expressed in the
amygdala (Carrasco et al., 2004), findings of alleviated morphine
dependence and subsequent naloxone-precipitated withdrawal
syndrome following intracerebroventricular administration of a
Gz-specific antiserum (Sanchez-Blazquez and Garzon, 1994) sug-
gest a potential involvement of Gz in opioid signaling in the CeA
during morphine withdrawal.
The overall effects of chronic morphine exposure in a given
CeA neuron may also depend on the presence of particular AC
isoforms in those cells (Avidor-Reiss et al., 1997; Watts and Neve,
2005). Most cells express two or more AC isoforms and nearly
all AC isoforms are expressed in the brain (Sadana and Dessauer,
2009). In general, a chronic treatment followed by agonist with-
drawal has been shown to increase the activity of AC-I, AC-V,
AC-VI, and AC-VIII isoforms, while reducing activity of the
AC-II, IV, and VII isoforms (Sunahara and Taussig, 2002). In
morphine dependence, an upregulation of AC signal transduc-
tion components is found in brain regions associated with drug
reinforcement and withdrawal (Sadana and Dessauer, 2009), and
is mediated by the AC-I, V, VI, and VIII isoforms (Avidor-Reiss
et al., 1997; Chakrabarti et al., 2001). By contrast, an over-
expression of ACVII results in enhanced acute and chronic actions
of morphine, and leads to more rapid development of tolerance
(Yoshimura et al., 2000).
In summary, these results indicate a cell-specific neuroadapta-
tion to chronic morphine treatment of the opioid system and its
effects on GABAergic transmission in CeA neurons. The cell-type
specific responses to acute morphine application during chronic
morphine treatment and morphine WD raise several questions:
(1)What afferent projections andwhat CeA neuronal populations
undergo neuroadaptive changes during the transition period
leading to development of morphine dependence? (2) What
mechanisms are regulating these chronic morphine-induced
circuitry- and cell-specific neuroadaptative changes in the CeA?
(3) What particular neuroadaptive changes of the opioid and
neurotransmitter systems in the CeA play a critical role in devel-
opment of morphine dependence and withdrawal? To address
these issues, further studies will be required, focusing on char-
acterization of cell types, circuitries, afferent projections and
their targeted CeA neurons with regard to their neurotransmitter,
neuropeptide, and cAMP contents.
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